Preterm birth drug app heads back to FDA

KV Pharmaceutical (NYSE: KV-B) is a step closer to getting its hands on a new drug to prevent preterm births. The company says that Hologic has resubmitted its FDA application for Gestiva, a drug KV paid $70 million for upfront back in January. KV also committed to $120 million in additional payments.

St. Louis, MO-based KV had announced its original intention to license the drug, also known at 17P, more than two years ago. But when the FDA failed to approve it by the beginning of 2009, the two companies went back to the drawing board.

"We believe this latest submission meets all the outstanding FDA requirements and marks an important milestone in the progression toward the potential approval and marketing of this product," says Greg Divis, president of Ther-Rx Corporation, KV's branded subsidiary.

- here's the KV release
- check out the story from the St. Louis Business Journal

Suggested Articles

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.